A biotech running a Phase 2 GLP-1 clinical trial at multiple sites identified a significant number of whole body DXA scans that were incorrectly acquired and analyzed. After reviewing the scans, Bracken's DXA experts recommended a standardized training program for site technologists and physicians to ensure consistent, high-quality acquisition — maintaining data integrity and salvaging the study.
What Made This Difficult
Inconsistent DXA scan quality across sites was threatening to compromise the trial's primary outcomes.
Site-level expertise in DXA whole body acquisition and analysis was highly variable across the multi-site trial
Frequent acquisition errors — including subtle patient motion artifacts — were compromising scan usability
A meaningful percentage of scans were already unusable, placing pressure on the trial's data integrity
The client needed a fast, practical solution deployable without slowing study timelines or overburdening site teams
How Bracken Solved It
Bracken designed and deployed a focused, expert-led DXA training program tailored to the trial's specific acquisition requirements — completed from initiation to delivery in under two weeks.
Expert Content Development
Bracken leveraged deep in-house DXA expertise to define the highest-impact training content — focusing specifically on acquisition precision, error prevention, and scan analysis fundamentals most relevant to GLP-1 body composition endpoints.
Professional Training Program Production
A ~15-minute training video was produced using PowerPoint, voiceover, and dynamic visual guidance — formatted for easy language translation and rapid deployment across all participating sites.
Knowledge Assessment & Expert Access
A brief quiz was designed to test trainee comprehension of critical material. Site personnel also gained direct access to Bracken's DXA expert to ask questions — supporting superior execution beyond the training content itself.
Measurable Outcomes
DXA scan quality in multi-site clinical trials doesn't fail because of poor equipment — it fails because of variable site training and no standardized acquisition protocol. Bracken's rapid-response training program addressed both, demonstrating that expert-led, precision-targeted training can protect trial integrity even after quality problems have been identified.
Common Questions About This Topic
GLP-1 trials frequently use whole body DXA to measure changes in lean mass, fat mass, and bone density as primary or secondary endpoints. Because weight loss from GLP-1 agents can affect both fat and muscle, accurate DXA acquisition is critical — errors in positioning, motion, or analysis directly compromise the trial's ability to detect these compositional changes.
Common errors include patient motion artifacts (even subtle movement causes scan artifacts), incorrect patient positioning, improper region-of-interest placement during analysis, and failure to follow site-specific scan protocols. Many are preventable with structured training.
Whole body DXA measures the distribution of lean tissue, fat tissue, and bone mineral content across the body. In GLP-1 obesity trials, it is used to assess whether weight loss is predominantly fat (desired) or lean mass (undesired) — a critical distinction for regulatory endpoints and clinical interpretation.
Bracken's experience demonstrates that a high-quality, multi-site DXA training program — including a professional training video, knowledge assessment, and expert access — can be designed and deployed in approximately two weeks from engagement initiation, without disrupting existing study timelines.
